ARA-290 vs Vilon

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Synthetic dipeptide Lys-Glu; modulates T-cell and NK cell activity; reduces age-related immune decline; normalizes cytokine production via epigenetic gene regulation

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic regulatory dipeptide signals that support T-lymphocyte activation and immune homeostasis diminished by age-related thymic involution. As the minimal active dipeptide unit of the Khavinson thymic bioregulator class, vilon is proposed to act through amino acid transporter uptake and modulation of intracellular signaling — including sphingomyelin pathway signal transduction in thymocytes — to restore T-cell activation thresholds and proliferative responses in immune cells from elderly subjects. Research has characterized natural and synthetic thymic peptides including vilon as therapeutic candidates for immune dysfunction, and experimental work has demonstrated that short Khavinson-class peptides modulate thymocyte blast transformation and sphingomyelin pathway signaling in immune cell preparations. Vilon has no FDA approval; evidence derives from Khavinson-series Russian preclinical and observational studies, and it has no regulatory approval in any major Western jurisdiction.